週五，生命科學工具公司Avantor Inc（紐約證券交易所代碼：AVTR）報告第四季度淨銷售額爲16.9億美元，同比下降2%，低於市場預期的17.1億美元。 外幣換算和臨牀服務業務剝離產生了負面影響，導致有機銷售增長僅爲1%。 公司淨收入從去年的9850萬美元增加到5.004億美元，調整後的淨收入爲1.839億美元，而去年同期爲1.667億美元。 公司報告調整後的息稅折舊及攤銷前利潤（EBITDA）爲3.077億美元，利潤率爲18.2%。調整後的營業收入爲2.794億美元，利潤率爲16.6%。 公司報告調整後的每股收益（EPS）爲0.27美元，較去年的0.29美元有所下降，但超出市場預期的0.26美元。 經營現金流爲1.733億美元，自由現金流爲2.221億美元。 Avantor總裁兼首席執行官Michael Stubblefield表示：“正如預期的那樣，我們在第四季度恢復了增長，調整後的EBITDA利潤率、調整後的EPS和自由現金流轉換率同比和環比均實現了增長。我們生物處理平臺實現了高個位數的增長，預計在我們集中執行力和改善的最終市場條件的推動下，繼續保持強勁增長。” 實驗室解決方案的淨銷售額爲11.3億美元，下降5%。外幣換算和臨牀服務業務剝離產生了負面影響，導致有機銷售額下降1%。 生物科學生產淨銷售額爲5.608億美元，增長4%。有機銷售增長4%。 前景展望：Avantor預計2025年有機營收增長爲1%-3%，而2024年則預計下降2%，調整後的EBITDA利潤率爲18%-19%。 公司預測調整後的每股收益在1.02美元至1.10美元之間，而市場預期爲1.10美元，預計自由現金流爲6.5億美元至7億美元。 股價走勢：截至週五盤前交易時段，AVTR股票下跌3.73%，報20.89美元。

以上內容來自Benzinga Earnings專欄，原文如下：

On Friday, Avantor Inc (NYSE:AVTR) reported fourth-quarter net sales of $1.69 billion, a decrease of 2% year-over-year, missing the consensus of $1.71 billion.

Foreign currency translation and Clinical Services divestiture had a negative impact, resulting in sales growth of 1% on an organic basis.

Net income increased to $500.4 million from $98.5 million a year ago, and adjusted net income was $183.9 million compared to $166.7 million in the comparable prior period.

Also Read: Nvidia Partners With Quantum-Si To Advance Single-Molecule Analysis

The life science tools company reported the adjusted EBITDA was $307.7 million, and the margin was 18.2%. Adjusted operating income was $279.4, with a margin of 16.6%.

The company reported an adjusted EPS of 27 cents, up from 29 cents a year ago, beating the consensus of 26 cents.

Operating cash flow was $173.3 million, while free cash flow was $222.1 million.

“As anticipated, we returned to growth in the fourth quarter and delivered sequential and year-over-year growth in adjusted EBITDA margin, adjusted EPS, and best-in-class free cash flow conversion. We grew our bioprocessing platform high-single-digits and expect continued strength driven by our focused execution and improving end market conditions,” said Michael Stubblefield, President and Chief Executive Officer.

Laboratory Solutions’ net sales were $1.13 billion, down 5%. Foreign currency translation and our Clinical Services divestiture had a negative impact, resulting in a 1% organic sales decline.

Bioscience Production net sales were $560.8 million, up 4%. Sales increased 4% organically.

Guidance: Avantor expects 2025 organic revenue growth of 1%-3% compared to 2024 decline of 2%, with adjusted EBITDA margin of 18%-19%

The company forecasts adjusted EPS of $1.02-$1.10 versus the consensus of $1.10 and expected free cash flow of $650 million—$700 million.

Price Action: AVTR stock is down 3.73% at $20.89 during the premarket session on last check Friday.

Read Next:

• Wynn’s Al Marjan Island Resort Expansion Gains Momentum, Secures Financing